SEC Comment Letter 0000000000-26-004843 to Entera Bio Ltd. (ENTX)
Entera Bio Ltd.
Date: May 12, 2026 · CIK: 0001638097 · Accession: 0000000000-26-004843
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295710
Letter
May 12, 2026 Miranda Toledano Chief Executive Officer Entera Bio Ltd. Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem, Israel 9112002 Re: Entera Bio Ltd. Registration Statement on Form S-3 Filed May 8, 2026 File No. 333-295710 Dear Miranda Toledano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sami B. Ghneim, Esq.
Show Raw Text
May 12, 2026 Miranda Toledano Chief Executive Officer Entera Bio Ltd. Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem, Israel 9112002 Re: Entera Bio Ltd. Registration Statement on Form S-3 Filed May 8, 2026 File No. 333-295710 Dear Miranda Toledano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sami B. Ghneim, Esq.